AdaptDx® continues to be used around the world in research designed to better understand age-related macular degeneration and hopefully develop more effective treatments.
Landmark AMD Study Relies on AdaptDx
Researchers at the University of Alabama School of Medicine conducted the Alabama Study on Early Age-Related Macular Degeneration (ALSTAR) to investigate the relationship between dark adaptation and AMD. Using AdaptDx®—which detects AMD with 90.6% accuracyii—they were able to determine dark adaptation is the first biomarker of AMD and that this functional symptom indicates subclinical AMD at least three years before structural changes are visible.ii The much-referenced ALSTAR Study was led by Cynthia Owsley, PhD, and published in Ophthalmology.
Major Study Participation
AdaptDx was chosen as a clinical endpoint in two current multi-year international studies of macular degeneration—MACUSTAR and ARIS.
The AdaptDx was selected as a key testing device in the MACUSTAR project, a five-year study aimed at reducing the disease burden of AMD worldwide. Currently funded with more than 16 million euros from the European Union and leading European pharmaceutical companies, the investigation expects to enroll 750 patients in seven countries across Europe.
The research project will be conducted at 20 clinical study centers in Europe, including:
- University Eye Clinic Bonn and the GRADE Reading Center Bonn
- Moorfields Eye Hospital
- University College
- City University
- Fondation voir et entendre Paris
- Coimbra Association for Innovation and Biomedical Research on Light and Image (AIBILI)
- Radound University Medical Center
- University of Sheffield
- European Clinical Research Infrastructures Network (ECRIN) Paris
AMD Ryan Initiative Study (ARIS):
Led by the National Eye Institute
This clinical study will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). Researchers will use the latest technologies, including AdaptDx, to measure function and visualize structures within the eye. The hope is to identify biomarkers of disease progression well before it advances to late-stage disease and causes vision loss.
All ARIS participants will undergo routine spectral domain optical coherence tomography (SD-OCT); and visual function will be measured by dark-adapted fundus perimetry and dark adaption. Dark-adaptation studies are relevant because AMD tends to first damage rod photoreceptors (the retinal cells that allow for vision under dim conditions) earlier than it does cone photoreceptors, which enable daylight vision. Researchers at each of the 20 ARIS study sites will track drusen volume changes as well as other findings on SD-OCT to see if they correspond to functional changes in visual acuity and dark adaptation.
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.